Key result
CMR detects myocardial hyperenhancement in ~50% of Anderson-Fabry disease patients.
Why the study?
The mechanism of left ventricular hypertrophy in Anderson-Fabry Disease is poorly understood, and the presence of myocardial fibrosis detectable by gadolinium enhanced cardiovascular magnetic resonance was hypothesized.
Does gadolinium enhanced cardiovascular magnetic resonance detect myocardial fibrosis in patients with Anderson-Fabry disease?
Cross-Sectional (n=26)
Does gadolinium enhanced cardiovascular magnetic resonance detect myocardial fibrosis in patients with Anderson-Fabry disease?
Gadolinium-enhanced CMR identifies a specific pattern of focal myocardial fibrosis (primarily basal infero-lateral wall) in a significant proportion of patients with Anderson-Fabry disease, correlating with left ventricular mass in males.
CMR detection of fibrosis may refine prognosis in Anderson-Fabry disease; extends imaging biomarkers for disease monitoring.
AIMS: Anderson-Fabry Disease (AFD), an X-linked disorder of sphingolipid metabolism, is a cause of idiopathic left ventricular hypertrophy but the mechanism of hypertrophy is poorly understood. Gadolinium enhanced cardiovascular magnetic resonance can detect focal myocardial fibrosis. We hypothesised that hyperenhancement would be present in AFD. METHODS AND RESULTS: Eighteen males (mean 43+/-14 years) and eight female heterozygotes (mean 48+/-12 years) with AFD underwent cine and late gadolinium cardiovascular magnetic resonance. Nine male (50%) had myocardial hyperenhancement ranging from 3.4% to 20.6% (mean 7.7+/-5.7%) of total myocardium; in males, percentage hyperenhancement related to LV mass index (r=0.78, P=0.0002) but not to ejection fraction or left ventricular volumes. Lesser hyperenhancement was also found in four (50%) heterozygous females (mean 4.6%). In 12 (92%) patients with abnormal gadolinium uptake, hyperenhancement occurred in the basal infero-lateral wall where, unlike myocardial infarction, it was not sub-endocardial. In two male patients with severe LVH (left ventricular hypertrophy) and systolic impairment there was additional hyperenhancement in other myocardial segments. CONCLUSIONS: These observations suggests that myocardial fibrosis occurs in AFD and may contribute to the hypertrophy and the natural history of the disease.
No takes yet. Share an insight, caveat, or question.
James Moon (2003) conducted a cross-sectional in Anderson-Fabry disease (n=26). Gadolinium enhanced cardiovascular magnetic resonance was evaluated on Myocardial hyperenhancement. Gadolinium enhanced cardiovascular magnetic resonance detected myocardial hyperenhancement in 50% of male and 50% of female patients with Anderson-Fabry disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: